Direct Comparison of Potency
Chlorthalidone is more potent than hydrochlorothiazide (HCTZ) on a milligram-for-milligram basis. It produces greater reductions in blood pressure at lower doses due to its longer duration of action and higher potency in inhibiting sodium reabsorption in the distal convoluted tubule.[1][2]
Typical dosing reflects this: chlorthalidone is effective at 12.5-25 mg daily, while HCTZ requires 25-50 mg daily for similar antihypertensive effects.[3]
How Potency Is Measured
Potency compares the dose needed for equal effects, often via diuretic response or blood pressure lowering. Studies show chlorthalidone 15 mg matches HCTZ 33.3 mg in urinary sodium excretion, confirming about 2- to 3-fold higher potency.[2][4] It also sustains effects longer (36-72 hours vs. HCTZ's 6-12 hours).[1]
Clinical Trial Evidence
Multiple trials, including ALLHAT, found chlorthalidone superior for stroke prevention and cardiovascular outcomes compared to HCTZ at equivalent doses.[5] A meta-analysis of 14 studies showed chlorthalidone lowers systolic blood pressure 3-4 mmHg more than HCTZ.[6]
Why Chlorthalidone Lasts Longer
Chlorthalidone's higher lipid solubility allows better tissue penetration and a plasma half-life of 40-60 hours, versus HCTZ's 6-15 hours. This leads to smoother 24-hour control and less electrolyte disturbance with chronic use.[1][7]
Side Effects and Risks
Both cause hypokalemia, hyponatremia, and hyperglycemia, but chlorthalidone's potency means more potassium loss at matched doses, often requiring supplementation. HCTZ may have a slightly better short-term tolerability profile.[3][8] Long-term, chlorthalidone shows fewer metabolic issues in some data.[6]
When Guidelines Prefer One Over the Other
U.S. guidelines (JNC 8, ACC/AHA) recommend chlorthalidone as first-line over HCTZ for hypertension due to stronger evidence and potency.[9] It's preferred in resistant hypertension or when 24-hour control matters.
Cost and Availability
Both are generic and inexpensive (under $10/month). No active patents limit access; chlorthalidone's original patent expired decades ago.[10]
[1] DrugPatentWatch.com - Chlorthalidone
[2] Earnest DL, et al. Clin Pharmacol Ther 1976;19:11-17.
[3] FDA Label - Hydrochlorothiazide
[4] Flack JM, et al. J Clin Hypertens 2002;4:239-244.
[5] Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
[6] Pressel S, et al. J Clin Hypertens 2011;13:251-261.
[7] Sica DA. J Clin Hypertens 2006;8:268-272.
[8] Ziai F, et al. Am J Kidney Dis 2006;48:587-593.
[9] James PA, et al. JAMA 2014;311:507-520.
[10] DrugPatentWatch.com - Hydrochlorothiazide